The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

According to The Business Research Company’s Global Market Report for Neuroendocrine Tumor Treatment in 2023, the market will rise from $1.73 billion in 2022 to $1.94 billion in 2023, with an 11.7% CAGR. The projected market size for global neuroendocrine tumor treatment is $2.88 billion by 2027, growing at a 10.5% CAGR.

What was the major driver in the neuroendocrine tumor treatment market?
Increasing neuroendocrine tumor cases will boost the neuroendocrine tumor treatment market. These rare tumors originate from neuroendocrine cells and require treatment to manage symptoms, control growth, and use radiation therapy for cell elimination. For instance, the American Society of Clinical Oncology (ASCO) reported over 12,000 annual neuroendocrine tumor diagnoses in the US, with approximately 171,000 people living with this condition in 2023. Additionally, Cancer Australia noted 5,437 neuroendocrine tumor diagnoses in Australia in 2022, accounting for 3.4% of all new cases in the same year. Hence, rising neuroendocrine tumor prevalence propels market growth.

View More On The Neuroendocrine Tumor Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

What was the key trend in the neuroendocrine tumor treatment market?
Clinical drug development is a prominent trend in the neuroendocrine tumor treatment market. Leading companies are innovating therapies to maintain market positions. For example, in October 2022, Viewpoint Molecular Targeting, Inc., a US-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) granted fast-track designation to expedite the development and review of [212Pb] VMT-a-NET, a targeted alpha-particle therapy, for treating SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs). This designation is reserved for drugs with potential to significantly enhance the treatment’s safety or effectiveness for severe conditions.

Which was the largest region in the neuroendocrine tumor treatment market?
North America was the largest region in the neuroendocrine tumor treatment market in 2022. The regions covered in the neuroendocrine tumor treatment industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the neuroendocrine tumor treatment market prominent players?
Major players in the neuroendocrine tumor treatment market are Pfizer Inc., F Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca, GlaxoSmithKline PLC, Takeda Pharmaceutical, Eli Lilly And Company, Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Servier, Teva Pharmaceutical Industries Ltd., Ipsen Pharma SAS, Exelixis Inc., Advanced Accelerator Applications SA, Hutchison Medipharma Ltd., Dauntless Pharmaceuticals Inc., Tarveda Therapeutics, GlycoMira Therapeutics Inc, AVEO Pharmaceuticals Inc., Progenics Pharmaceuticals Inc., Callisto Pharmaceuticals Pvt Ltd., and Chiasma Inc.

Key neuroendocrine tumor treatment market segments
The global neuroendocrine tumor treatment market is segmented –
1) By Product: Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others Products
2) By Indication: Lungs, Pancreas, Gastrointestinal, Others Indications
3) By End-Users: Hospitals, Oncology Centers, Other End-Users

Request A Sample Of The Global Neuroendocrine Tumor Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12248&type=smp

The Neuroendocrine Tumor Treatment Global Market Report 2023  provides a comprehensive overview on the neuroendocrine tumor treatment market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Tumor Ablation Therapy Devices Global Market Report 2023
Tumor Embolization Devices Global Market Report 2023
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model